Allopurinol
Treatment for Gout
Typical Dosage: 100-800 mg daily, titrated
Effectiveness
85%
Safety Score
65%
Clinical Trials
71
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
100-800 mg daily, titrated
Time to Effect
Days-weeks (sUA reduction), 6-12 months (flare reduction)
Treatment Duration
lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$30
Monitoring:$300
Side Effect Mgmt:$50
Total Annual:$380
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
2.5
Outcome-Based Costs
Cost per Responder
$447
Cost per Remission
$585
Comparison vs Febuxostat
Cost Difference
$-290/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
DOMINATESBetter + cheaper
Allopurinol Outcomes
for Gout
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+85%
Remission Rate
+65%
Common Side Effects
Skin rash
+3%
Diarrhea/Nausea
+2%
Gout flares (initiation)
+10%
Active Clinical Trials
3 active trials recruiting for Allopurinol in Gout
A Study of Dotinurad Versus Allopurinol in Participants With Gout
NCT07089875RECRUITINGPHASE3
500 participants
INTERVENTIONAL
Birmingham, United States +71 more
Started: Aug 1, 2025
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
NCT05665699ACTIVE NOT RECRUITINGPHASE2
80 participants
INTERVENTIONAL
Birmingham, United States +18 more
Started: Apr 17, 2023
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
NCT07089888RECRUITINGPHASE3
250 participants
INTERVENTIONAL
Birmingham, United States +62 more
Started: Aug 4, 2025
Completed Clinical Trials
13 completed trials for Allopurinol in Gout
Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/Gout
NCT01129648COMPLETEDPHASE2
87 participants
INTERVENTIONAL
Scottsdale, United States +17 more
Started: May 1, 2010
Allopurinol Outcome Study
NCT01391325COMPLETEDPHASE4
1.74K participants
INTERVENTIONAL
Birmingham, United States +172 more
Started: Jul 1, 2011
Combining Lesinurad With Allopurinol in Inadequate Responders
NCT01510158COMPLETEDPHASE3
607 participants
INTERVENTIONAL
Athens, United States +164 more
Started: Jan 1, 2012
Initiation of Allopurinol at First Medical Contact for Acute Attacks of Gout
NCT01310673COMPLETEDPHASE4
57 participants
INTERVENTIONAL
White River Junction, United States
Started: Jan 1, 1998
A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout
NCT04956432COMPLETEDPHASE3
779 participants
INTERVENTIONAL
Shanghai, China
Started: Jun 15, 2021
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients with Hyperuricemia
NCT06056570COMPLETEDPHASE1, PHASE2
20 participants
INTERVENTIONAL
Clearwater, United States +3 more
Started: Oct 4, 2023
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
NCT02082769COMPLETEDPHASE3
504 participants
INTERVENTIONAL
Started: Jul 1, 2011
Optimal Administration of Allopurinol in Dialysis Patients
NCT02477488COMPLETEDPHASE4
50 participants
INTERVENTIONAL
Montreal, Canada
Started: Jun 1, 2015
A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout
NCT01736514COMPLETEDPHASE3
109 participants
INTERVENTIONAL
Kaohsiung City, Taiwan +3 more
Started: Mar 1, 2011
Genetics of Hyperuricemia Therapy in Hmong
NCT02371421COMPLETED
80 participants
OBSERVATIONAL
Minneapolis, United States
Started: Jun 1, 2014
Does Allopurinol Prolong a Treated, Acute Gout Flare?
NCT01988402COMPLETEDPHASE4
35 participants
INTERVENTIONAL
Lackland Air Force Base, United States
Started: Dec 1, 2007
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
NCT05818085COMPLETEDPHASE2, PHASE3
300 participants
INTERVENTIONAL
Tempe, United States +56 more
Started: Aug 11, 2023
Allopurinol Combination Study
NCT01001338COMPLETEDPHASE2
227 participants
INTERVENTIONAL
Phoenix, United States +43 more
Started: Oct 1, 2009
Showing 20 of 72 total trials